TG Therapeutics Completes Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma or Follicular Lymphoma

David Linetsky
Point-of-Care Marketing

Pat Purcell
Meeting Engagement

Bud Bilanich
Success Coach

Stacey Gandler
Brand Nourishment

Paul Theisen
Patient Acquisition

Frank Burrell
Scientific Storytelling

Joey Cohen
Medication Adherence

Brenda Snow
Authentic Patient Voice

Daniel Sontupe
Market Access

Matthew Durham
Omnidynamic Marketing

Liz Kane
Impactful Strategy

Amy Giles
Increasing Engagement

Matt Turner
Patient Affordability

Suma Ramadas, PhD
Medical Affairs